A detailed history of Black Rock Inc. transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,343,193 shares of INZY stock, worth $17.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,343,193
Previous 3,088,653 8.24%
Holding current value
$17.5 Million
Previous $23.7 Million 36.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.33 - $7.31 $1.1 Million - $1.86 Million
254,540 Added 8.24%
3,343,193 $14.9 Million
Q1 2024

May 10, 2024

BUY
$4.14 - $7.66 $191,777 - $354,834
46,323 Added 1.52%
3,088,653 $23.7 Million
Q4 2023

Feb 13, 2024

BUY
$2.71 - $4.5 $2.18 Million - $3.61 Million
802,588 Added 35.83%
3,042,330 $13 Million
Q3 2023

Nov 13, 2023

BUY
$4.09 - $7.0 $1.23 Million - $2.1 Million
300,082 Added 15.47%
2,239,742 $9.41 Million
Q2 2023

Aug 11, 2023

BUY
$4.93 - $6.74 $7.34 Million - $10 Million
1,488,467 Added 329.9%
1,939,660 $10.8 Million
Q1 2023

May 12, 2023

BUY
$1.3 - $5.73 $32,459 - $143,072
24,969 Added 5.86%
451,193 $2.59 Million
Q4 2022

Feb 13, 2023

SELL
$1.05 - $2.82 $2,317 - $6,223
-2,207 Reduced 0.52%
426,224 $447,000
Q3 2022

Nov 14, 2022

SELL
$2.57 - $5.45 $5,368 - $11,385
-2,089 Reduced 0.49%
428,431 $1.15 Million
Q2 2022

Aug 12, 2022

SELL
$3.2 - $5.96 $1.43 Million - $2.67 Million
-447,880 Reduced 50.99%
430,520 $2.05 Million
Q1 2022

May 12, 2022

BUY
$3.87 - $7.55 $160,225 - $312,585
41,402 Added 4.95%
878,400 $3.59 Million
Q4 2021

Feb 10, 2022

SELL
$5.58 - $11.5 $355,563 - $732,791
-63,721 Reduced 7.07%
836,998 $5.71 Million
Q3 2021

Nov 09, 2021

BUY
$11.12 - $19.4 $9,407 - $16,412
846 Added 0.09%
900,719 $10.4 Million
Q2 2021

Aug 11, 2021

BUY
$15.19 - $21.2 $13.7 Million - $19.1 Million
899,873 New
899,873 $15.3 Million

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $210M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.